Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H
Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:452-7. doi: 10.1111/j.1525-1438.2006.00418.x.
We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells. This study aimed at investigating whether p27 expression could be a predicting marker to evaluate the effectiveness of MPA therapy. The clinical responses of 15 patients with endometrial carcinoma treated with MPA were examined. p27 expression was evaluated by immunohistochemical staining. Percentage of positive nuclear staining was expressed as a strongly positive (SP) labeling index (LI). Before MPA treatment, SP LIs in the effective and noneffective groups were 22.6 +/- 14.3% and 9.1 +/- 9.2%. At 1-6 weeks in the MPA treatment, SP LIs increased in both groups and were significantly higher than those before the therapy. At 7-12 weeks, SP LIs in both groups decreased to the level of pretherapy. At 13-18 weeks, SP LIs in the effective group were 14.9 +/- 5.7%, whereas in the noneffective group, 1.1 +/- 2.0%. The former was significantly higher than the latter. p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.
我们报道，醋酸甲羟孕酮（MPA）诱导产生的p27可能参与了孕激素诱导的人子宫内膜腺癌细胞生长抑制过程。本研究旨在调查p27表达是否可作为评估MPA治疗效果的预测标志物。检测了15例接受MPA治疗的子宫内膜癌患者的临床反应。通过免疫组织化学染色评估p27表达。阳性核染色百分比表示为强阳性（SP）标记指数（LI）。MPA治疗前，有效组和无效组的SP LI分别为22.6±14.3%和9.1±9.2%。在MPA治疗的1 - 6周，两组的SP LI均升高，且显著高于治疗前。在7 - 12周，两组的SP LI均降至治疗前水平。在13 - 18周，有效组的SP LI为14.9±5.7%，而无效组为1.1±2.0%。前者显著高于后者。p27表达可在MPA治疗4个月的早期阶段预测MPA治疗子宫内膜癌的效果，且可能是MPA的一个有用的预测标志物。
